Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.

× No keyword cloud information.

41 in total

1. Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors: S C TRUELOVE; L J WITTS
Journal: Br Med J Date: 1955-10-29

Review 2. Ulcerative Colitis Care Pathway.

Authors: Themistocles Dassopoulos; Russell D Cohen; Ellen J Scherl; Ronald M Schwartz; Lawrence Kosinski; Miguel D Regueiro
Journal: Gastroenterology Date: 2015-05-27 Impact factor: 22.682

3. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.

Authors: R W Chapman; W S Selby; D P Jewell
Journal: Gut Date: 1986-10 Impact factor: 23.059

4. There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center.

Authors: Shailja C Shah; Steven Naymagon; Benjamin L Cohen; Bruce E Sands; Marla C Dubinsky
Journal: J Clin Gastroenterol Date: 2018-04 Impact factor: 3.062

5. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.

Authors: G J Mantzaris; A Hatzis; P Kontogiannis; G Triadaphyllou
Journal: Am J Gastroenterol Date: 1994-01 Impact factor: 10.864

6. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease.

Authors: J Maté-Jiménez; C Hermida; J Cantero-Perona; R Moreno-Otero
Journal: Eur J Gastroenterol Hepatol Date: 2000-11 Impact factor: 2.566

7. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors: David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal: Lancet Date: 2012-10-10 Impact factor: 79.321

8. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

Authors: D P Jewell; S C Truelove
Journal: Br Med J Date: 1974-12-14

9. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Authors: John G Williams; M Fasih Alam; Laith Alrubaiy; Ian Arnott; Clare Clement; David Cohen; John N Gordon; A Barney Hawthorne; Mike Hilton; Hayley A Hutchings; Aida U Jawhari; Mirella Longo; John Mansfield; Jayne M Morgan; Frances Rapport; Anne C Seagrove; Shaji Sebastian; Ian Shaw; Simon P L Travis; Alan Watkins
Journal: Lancet Gastroenterol Hepatol Date: 2016-09

Review 10. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.

Authors: Siddharth Singh; John George; Brigid S Boland; Niels Vande Casteele; William J Sandborn
Journal: J Crohns Colitis Date: 2018-05-25 Impact factor: 9.071

66 in total

1. Hospital Management of Acute Severe Ulcerative Colitis.

Authors: Joseph Feuerstein
Journal: Gastroenterol Hepatol (N Y) Date: 2021-03

2. C. difficile and the Patient with Inflammatory Bowel Disease: A Testing Dilemma.

Authors: Varun Moktan; Emily Jonica; Zhou Li; Donna Jane Hata; Francis A Farraye
Journal: Dig Dis Sci Date: 2021-03 Impact factor: 3.199

3. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci.

Authors: Kasumi Hishinuma; Rintaro Moroi; Daisuke Okamoto; Yusuke Shimoyama; Masatake Kuroha; Hisashi Shiga; Yoichi Kakuta; Yoshitaka Kinouchi; Atsushi Masamune
Journal: Inflamm Intest Dis Date: 2021-09-02

Review 4. Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape.

Authors: Elyse A Linson; Stephen B Hanauer
Journal: Curr Gastroenterol Rep Date: 2021-08-02

Review 5. Vedolizumab in Inflammatory Bowel Disease: West versus East.

Authors: Prasanta Debnath; Pravin M Rathi
Journal: Inflamm Intest Dis Date: 2021-01-27

6. Network Meta-Analyses in Inflammatory Bowel Disease.

Authors: Siddharth Singh
Journal: Gastroenterol Hepatol (N Y) Date: 2020-06

7. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.

Authors: Siddharth Singh; Herbert C Heien; Jeph Herrin; Parambir S Dulai; Lindsey Sangaralingham; Nilay D Shah; William J Sandborn
Journal: Clin Gastroenterol Hepatol Date: 2021-02-25 Impact factor: 11.382

Review 8. Acute Severe Colitis: The Need for Joint Management between Gastroenterologists and Surgeons.

Authors: Phillip Fleshner; Gil Y Melmed
Journal: Clin Colon Rectal Surg Date: 2022-01-17

Review 9. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough.

Authors: Aderson Omar Mourão Cintra Damião; Natália Sousa Freitas Queiroz
Journal: Clin Colon Rectal Surg Date: 2022-01-17

Review 10. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management.

Authors: Simon J Hong; Seymour Katz
Journal: Therap Adv Gastroenterol Date: 2021-07-03 Impact factor: 4.409